|
Dec 9
|
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)
|
|
Dec 9
|
New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
|
|
Dec 7
|
HRMY or GMAB: Which Is the Better Value Stock Right Now?
|
|
Dec 5
|
Capital Increase in Genmab as a Result of Employee Warrant Exercise
|
|
Nov 28
|
AbbVie (ABBV) Lymphoma Drug Gets FDA Breakthrough Therapy Tag
|
|
Nov 27
|
Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma
|
|
Aug 24
|
Nvidia upgraded, Estee Lauder downgraded: Wall Street's top analyst calls
|